Advertisements


When a disease is god"s "blessing"

Mata, the goddess, has come upon me, the gardener said.....»»

Category: topSource: business-standardMay 19th, 2017

Studying abroad? Buy adequate travel cover

Often, this mandatory requirement gets the least attention as buying in India is usually cheaper unless you have a pre-existing disease.....»»

Category: topSource: business-standard17 hr. 12 min. ago

Celgene Down on Discontinued Crohn"s Disease Drug Study

Shares of .....»»

Category: futuresSource: nasdaqOct 20th, 2017

Infectious disease biotech Arsanis files for a $58 million IPO

Arsanis which is developin.....»»

Category: futuresSource: nasdaqOct 20th, 2017

Celgene Down on Discontinued Crohn"s Disease Drug Study

Shares of Celgene Corporation (CELG) declined after the company announced that a phase III trial, REVOLVE, (CD-002) on pipeli.....»»

Category: worldSource: nytOct 20th, 2017

Celgene: No Surprise? Its 10% Drop Says Different.

The drug maker's share price is plunging today after the company abandoned studies of an experimental Crohn's disease treatment, surprising investors. But analysts say that concerns have been mounting about the drug......»»

Category: blogSource: barronsOct 20th, 2017

Pipeline Bomb: Analysts Review Celgene"s Crohn"s Diseases Failure

Celgene Corporation (NASDAQ: CELG) stock plummeted 10 percent Friday after the company reported that its testing of GED-0301 for treatment of Crohn’s disease has failed to meet its e.....»»

Category: blogSource: benzingaOct 20th, 2017

Celgene"s Pipeline In Question After GED Failure

After announcing the termination of its mongerson program for Crohn’s disease, Celgene Corporation (NASDAQ: CELG) is looking more and.....»»

Category: blogSource: benzingaOct 20th, 2017

Celgene: No Surprise? It’s 10% Drop Says Different.

The drug maker's share price is plunging today after the company abandoned studies of an experimental Crohn's disease treatment, surprising investors. But analysts say that concerns have been mounting about the drug......»»

Category: blogSource: barronsOct 20th, 2017

Conatus" Liver Disease Drug Gets Orphan Drug Tag in the EU

Conatus (CNAT) secures orphan drug designation for its pipeline candidate, IDN-7314, granted by the EMA. The candidate currently undergoes a phase II study on curing primary.....»»

Category: worldSource: nytOct 20th, 2017

What To Do With Celgene Now With Major Catalysts Gone

Celgene Corporation (NASDAQ: CELG)’s discontinuation of mongerson for Crohn’s disease is decidedly negative. The stock plunged 8.2 percent in premarket trading. But the extent of justified pessimism depends on prior expectations. .....»»

Category: blogSource: benzingaOct 20th, 2017

UBS Cuts Price Target On Celgene To $146 As GED Drops Out

The discontinuation of Celgene Corporation (NASDAQ: CELG)’s mongerson for Crohn’s disease prompted a 6.6-percent sell-off in Friday’s premarket trading. But UBS was undeterred by the announcement. .....»»

Category: blogSource: benzingaOct 20th, 2017

Celgene downgraded to neutral at Baird for "increasing risks to long-term goals"

Celgene Corp. was downgraded to neutral at Baird Equity Research on Friday after the drugmaker abandoned three Crohn's disease drug trials late Thursday. Baird analyst Brian Skorney also lowered the company's price target.....»»

Category: topSource: marketwatchOct 20th, 2017

Celgene stock drops 5.3% after company abandons three Crohn"s disease drug trials

This is a Real-time headline. These are breaking news, delivered the minute it happens, delivered ticker-tape style. Visit www.marketwatch.com or the quote page for more information about this breaking news......»»

Category: topSource: marketwatchOct 20th, 2017

Celgene down 6% after discontinuing Crohn"s disease trials

This is a Real-time headline. These are breaking news, delivered the minute it happens, delivered ticker-tape style. Visit www.marketwatch.com or the quote page for more information about this breaking news......»»

Category: topSource: marketwatchOct 19th, 2017

Celgene shares drop after Crohn"s disease drug trials halted

Celgene Corp. shares dropped in the extended session Thursday after the biotech com.....»»

Category: topSource: marketwatchOct 19th, 2017

Analyst Sees 243% Upside For Corbus Pharma Following Positive Clinical Data

Shares of Corbus Pharmaceuticals Holdings Inc (NASDAQ: CRBP) gained 10 percent on Thursday in reaction to the company's encouraging update to a phase 2 trial of its autoimmune disease drug called anabasum......»»

Category: blogSource: benzingaOct 19th, 2017

Imprimis Launches 99-Cent Generic Drug To Compete With Allergan"s Restasis

Imprimis Pharmaceuticals, Inc. (NASDAQ: IMMY) announced Thursday the release of a 99-cent alternative to Allergan PLC Ordinary Shares (NYSE: AGN)'s Restasis to address the 30 million Americans suffering from Dry Eye Disease. read more.....»»

Category: blogSource: benzingaOct 19th, 2017

Corbus Pharma shares surge 21% on mid-stage results for inflammatory disease drug

Corbus Pharmaceutical Holdings Inc. shares surged 21.4% in premarket trade on Thursday after the company reported positive results from a phase 2 trial of its autoimmune disease drug. The drug, anabasum, is inten.....»»

Category: topSource: marketwatchOct 19th, 2017

Corbus Pharma shares surge 6% on mid-stage results for autoimmune disease drug

This is a Real-time headline. These are breaking news, delivered the minute it happens, delivered ticker-tape style. Visit www.marketwatch.com or the quote page for more information about this breaking news......»»

Category: topSource: marketwatchOct 19th, 2017

Howard Hughes marks completion of second Kakaako tower

The Howard Hughes Corp. on Wednesday marked the completion of the 317-unit Anaha in Honolulu, its second luxury mixed-use condominium tower in the developer’s Ward Village in Kakaako, with a traditional Hawaiian blessing. The $400 million distinc.....»»

Category: topSource: bizjournalsOct 19th, 2017